CPT code 21013 denotes surgical excision of a soft tissue tumor on the face or scalp, with tissue submitted for pathology to rule out cancer. This procedure is clinically important because facial and scalp masses, while often benign, require removal and histologic evaluation to exclude malignancy and to guide further care. Nationally, appropriate coding of these excisions affects both clinical documentation and payment for surgical services performed in ambulatory surgery centers, hospital outpatient departments, and office-based surgical settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the procedure, common payers and payer considerations, and the types of benchmarks and policy details typically associated with surgical excision codes. The publication summarizes expected sites of service and the clinical rationale for sending specimens for laboratory analysis. It also outlines the range of modifiers commonly encountered for surgical services and notes where input was not provided.

This resource is intended for billing professionals, surgeons, and policy analysts seeking a national overview of CPT code 21013, its clinical purpose, and the payer landscape relevant to coding and claims processing.